Differentiation of low-molecular-weight heparins: Impact on the future of the management of thrombosis

Seminars in Thrombosis and Hemostasis

Volumn 30, Issue SUPPL. 1, 2004, Pages 89-104

  Fareed, Jawed ^a   Ma, Qing ^a   Florian, Michelle ^a   Maddineni, Jyothi ^a   Iqbal, Omer ^a   Hoppensteadt, Debra A ^a   Bick, Rodger L ^b  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Anticoagulants; Antithrombotic; Differentiation; Generic drugs; Low molecular weight heparins

Indexed keywords

ABCIXIMAB; ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; ARDEPARIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CERTOPARIN; CLOPIDOGREL; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; GENERIC DRUG; HEPARIN; HEPARINOID; HIRUDIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; OLIGOPEPTIDE; PARNAPARIN; REVIPARIN; SERINE PROTEINASE INHIBITOR; TICLOPIDINE; TINZAPARIN; TISSUE FACTOR PATHWAY INHIBITOR; VON WILLEBRAND FACTOR; YM 337;

ANTICOAGULATION; CELL DIFFERENTIATION; CHEMICAL ANALYSIS; CONFERENCE PAPER; DEEP VEIN THROMBOSIS; DEPOLYMERIZATION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG HALF LIFE; ENZYME ASSAY; FUTUROLOGY; HUMAN; PRIORITY JOURNAL; SURGICAL PATIENT; THROMBOGENESIS; THROMBOSIS;

BLOOD COAGULATION; FORECASTING; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; THROMBOSIS;

EID: 1842504014     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-823007     Document Type: Conference Paper

References (24)

1. Fareed J, Hoppensteadt D. Management of thrombotic and cardiovascular disorders in the 21st century. In: Sasahara AA, Loscalzo J, eds. New Therapeutic Agents in Thrombosis and Thrombolysis, 2nd ed. New York: Marcel Dekker, 2002:687-693
2. Linhardt RJ, Gunay SN. Production and chemical processing of low molecular weight heparins. Semin Thromb Hemost 1999;25(suPPl 3):5-16
3. Casu B, Torri G. Structural characterization of low molecular weight heparins. Semin Thromb Hemost 1999;25(suppl 3):17-25
4. Young E, Wells P, Holloway S, WeitzJ, Hirsh J. Ex vivo and in vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb Haemost 1994;71:300-304
5. Houbouyan L, Padilla A, Gray E, Longstaff C, Barrowcliffe TW. Inhibition of thrombin generation by heparin and LMW heparins: a comparison of chromogenic and dotting methods. Blood Coagul Fibrinolysis 1996;7:24-30
6. Montalescot G, Collet JP, Lison L, Choussat R, Anki A. Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina. J Am Coll Cardiol 2000;36:110-114
7. Marmur JD, Anand SX, Bagga RS, et al. The activated clotting time can be used to monitor the low molecular weight heparin dalteparin after intravenous administration. J Am Coll Cardiol 2003;41:394-402
8. Kaiser B, Kirchmaier M, Breddin KH, Fu K, Fareed J. Preclinical biochemistry and pharmacology of low molecular weight heparins in vivo: studies of venous and arterial thrombosis. Semin Thromb Hemost 1999;25(suppl 3):35-42
9. Dietrich CP, Shinjo SK, Moraes FA, et al. Structural features and bleeding activity of commercial low molecular weight heparins: neutralization by ATP and protamine. Semin Thromb Hemost 1999;25(suppl 3):43-50
10. Cornelli U, Fareed J. Human pharmacokinetics of low molecular weight heparins. Semin Thromb Hemost 1999;25(suppl 3):57-61
11. Nader HB, Walenga JM, Berkowitz SD, Ofosu F, Hoppensteadt DA, Cella G. Preclinical differentiation of low molecular weight heparins. Semin Thromb Hemost 1999;25(suppl 3):63-72
12. Fareed J, Fu L, Yang LH, Hoppensteadt DA. Pharmacokinetics of low molecular weight heparins in animal models. Semin Thromb Hemost 1999;25(suppl 3):51-55
13. Mammen EF, Arcelus J, Messmore H, Altman R, Nurmohamed M, Eldor A. Clinical differentiation of low molecular weight heparins. Semin Thromb Hemost 1999;25(suppl 3):135-144
14. Nightingale SL. From the Food and Drug Administration. JAMA 1993;270:1672
15. McCart GM, Kayser S. Therapeutic equivalency of low molecular weight heparins. Ann Pharmcother 2002;36:1042-1057
16. Nenci G. Low molecular weight heparins: are they interchangeable? No. J Thromb Hemost 2003;1:12-13
17. Merli G, Vanscoy G, Rihn TL, Grace JB III, McCormick W. Applying scientific criteria to therapeutic interchange: a balanced analysis of low molecular weight heparins. J Thromb Thrombolysis 2001;11:247-259
18. Cohen M. Low molecular weight heparins in the management of unstable angina/non-Q-wave myocardial infarction. Semin Thromb Hemost 1999;25(suppl 3):113-121
19. Gulba D. Differentiation of low molecular weight heparins in acute coronary syndromes: an interventionalist's perspective. Semin Thromb Hemost 1999;25(suppl 3):123-127
20. Leong W, Hoppensteadt DA. Generic forms of low molecular weight heparins. Some practical issues. Clin Appl Thromb Hemost 2003;9:293-297
21. Jeske W, Fareed J. In vitro studies on the biochemistry and pharmacology of low molecular weight heparins. Semin Thromb Hemost 1999;25(suppl 3):27-33
22. Fareed J, Walenga JM, Hoppensteadt D, Huan X, Racanelli A. Comparative study on the in vitro and in vivo activities of seven low-molecular-weight heparins. Haemostasis 1988; 18(suppl 3):3-15
23. Fareed J, Walenga JM, Williamson K, Emanuele RM, Kumar A, Hoppensteadt D. Studies on the antithrombotic effects and pharmacokinetics of heparin fractions and fragments. Semin Thromb Hemost 1985;11:56-74
24. Abboud L. Bush acts to speed generics to market. The Wall Street Journal. June 12, 2003:A3